

## Unique CPOS-USC Publications - 2014

1. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, Garrels K, Hotte S, Kattan MW, Raghavan D, Saad F, Taplin ME, Walker-Dilks C, Williams J, Winquist E, **Bennett CL**, Wootton T, Rumble RB, Dusetzina SB, and Virgo KS. Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. *J Clin Oncol* 10.1200/JCO.2013.54.8404.
2. **Bennett CL**, Jacob S, Hymes J, Usvyat LA, Maddux FW. Anaphylaxis and hypotension after administration of peginesatide. *N Engl J Med*. 2014 May 22;370(21):2055-6. doi: 10.1056/NEJMc1400883.
3. **Bennett CL**, **Bian J**. Erythropoiesis-stimulating agents and quality of life: personal journeys of a cancer survivor, oncologist, and two cancer health services researchers. *Br J Cancer*. 2014 Jul 29;111(3):421-312.
4. **Bennett CL**, Chen B, Hermanson T, Wyatt MD, **Schulz RM**, Georgantopoulos P, Kessler S, Raisch DW, Qureshi ZP, **Lu ZK**, **Love BL**, Noxon V, Bobolts L, Armitage M, **Bian J**, Ray P, Ablin RJ, Hrushesky WJ, Macdougall IC, Sartor O, Armitage JO. Regulatory and clinical considerations for biosimilar oncology drugs. *Lancet Oncol*. 2014 Dec;15(13):e594-e605. doi: 10.1016/S1470-2045(14)70365-1. Epub 2014 Nov 24.
5. Bland C, **Sutton SS**, **Dunn BL**. What are the latest recommendations for managing severe sepsis and septic shock? *JAAPA* 2014;27:15-19.
6. Bland C, **Bookstaver B**, **Lu Z**, **Dunn BL**, Rumley K. Musculoskeletal safety outcomes of patients receiving Daptomycin with HMG-CoA reductase inhibitors. *Antimicrob Agents Chemother* 2014;58:5726-5731.
7. **Bookstaver PB**, **Justo JA**. Commentary on "Incidence and predictors of vancomycin-associated nephrotoxicity." *South Med J*. 2014 Jun;107(6):389-90.
8. **Bookstaver PB**, Capino AC, Bookstaver NK. A pharmacy concierge service to optimize fidaxomicin therapy. *Am J Health-Syst Pharm* 2014;71:986-7.
9. **Bookstaver PB**, Felder TM, Quidley AM, **Ragucci K**, **Nappi J**, Draper HM. Barriers to the pursuit of scholarly activities by pharmacy residents. *Currents in Pharmacy Teaching and Learning* 2014;7(1):40-6.
10. Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, Moskowitz AJ, Rook AH, Jalan P, Loren AW, Landsburg D, Coyne T, Tsai D, Raisch DW, **Norris LB**, **Bookstaver PB**, Sartor O, **Bennett CL**. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases

from the Southern Network on Adverse Reactions (SONAR) project. *Cancer*. 2014 Aug 15;120(16):2464-71. doi: 10.1002/cncr.28712. Epub 2014 Apr 25.

11. **Caulder CR**, Sloan A, Ahmed Y, **Bookstaver PB**. Infusion-Related Reaction following Daptomycin 2-minute Rapid Intravenous Administration. *Hosp Pharm* 2014;49:644-6.
12. Davis-Ajami ML, **Wu J**, Downton K, Ludeman E, Noxon V. Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. *Biologics: Targets and Therapy* 2014;8:155-67.
13. Davis-Ajami ML, **Wu J**, Fink JC. Differences in Health Services Utilization and Costs between Antihypertensive Medication Users versus Nonusers in Adults with Diabetes and Concomitant Hypertension from Medical Expenditure Panel Survey Pooled Years 2006 to 2009. *Value in Health* 2014;14(1): 51-61.
14. Davis TC, Arnold CL, **Bennett CL**, Wolf MC, Reynolds C, Liu D, Rademaker A. Strategies to Improve Repeat Fecal Occult Blood Testing Cancer Screening. *Cancer Epidemiol Biomarkers Prev* 2014 Jan;23(1):134-43. doi: 10.1158/1055-9965.EPI-13-0795. Epub 2013 Nov 5.
15. Davis TC, Rademaker A, **Bennett CL**, Wolf MS, Carias E, Reynolds C, Liu D, Arnold CL. Improving mammography screening among the medically underserved. *J Gen Intern Med*. 2014 Apr;29(4):628-35. doi: 10.1007/s11606-013-2743-3. Epub 2013 Dec 24.
16. Hamed S, **Bennett CL**, Demiot C, Ullmann Y, Teot L, Desmoulière A. Erythropoietin, a novel repurposed drug: an innovative treatment for wound healing in patients with diabetes mellitus. *Wound Repair Regen*. 2014 Jan-Feb;22(1):23-33. doi: 10.1111/wrr.12135. Epub 2013 Dec 13.
17. Hawes EM, **Maxwell WD**, Ford SK, Mangun J, Lin FC. Effect of pharmacist intervention on medication discrepancies and healthcare resource utilization at post-hospitalization care transitions. *Journal of Primary Care and Community Health*. 2014;5:14-18.
18. Hermanson T, Sartor O, Ablin RJ, **Bennett CL**. Editorial comment re: Technology Diffusion and Prostate Cancer Quality of Care Urology. 2014 Nov 14; 84(5):1066. *Urology*. 2014 Nov;84(5):1072. doi: 10.1016/j.urology.2014.06.068. Epub 2014 Oct 24.
19. Hermanson T, **Norris LB**, **Bian J**, Sartor O, **Bennett CL**. Toxicity and costs associated with new cancer drugs: international implications. *J Clin Oncol* 2014; Nov 10; 32(32): 3591-2.
20. Jarkowski A, **Norris L**, Trinh V. Controversies in the management of Advanced melanoma: "Gray areas amid the "Black and Blue". *Ann Pharmacother* 2014; 48(11): 1456-68.

21. **Justo J, Bookstaver PB**. Antibiotic lock therapy: review of technique and logistical challenges. *Infect Drug Resist*. 2014 Dec 12;7:343-63.
22. **Justo J**, Gauthier TP, Scheetz MH, Chahine EB, **Bookstaver PB**, Gallagher JC, Hermsen ED, DePestel DD, Ernst EJ, Jacobs DM, Esterly JS, Suda KJ, Olsen KM, Abbo LM, MacDougall C. Knowledge and attitudes of doctor of pharmacy students regarding the appropriate use of antimicrobials. *Clin Infect Dis*. 2014 Oct 15;59(suppl 3):S162-S169.
23. Kessler SJ, **Bennett CL**. Forewarned is forearmed: erythropoietin use in CKD patients with cancer. *J Nephrol*. 2013 Sep-Oct;26(5):805-6. doi: 10.5301/jn.5000334. Epub 2013 Sep 12.
24. **Love BL**, Johnsson A, Smith LS. Linaclotide: A Novel Agent for Chronic Constipation and Irritable Bowel Syndrome. *American Journal of Health-System Pharmacy* 2014;71:1081-91.
25. **Lu ZK**, Kessler, SJ, **Schulz R**, Bian J, Chen B, **Wu J**, Noxon V, Rao G, Leibnitz R, Restaino J, **Maxwell WD**, **Norris LB**, Qureshi ZP, Martin L, **Love BL**, **Bookstaver PB**, **Sutton SS**, Fayad R, Jacob S, Georgantopoulos P, Sartor O, Yarnold PR, Huff D, Hrushesky WJM, Raisch DW, Ablin R, **Bennett CL**. Systemic approach to pharmacovigilance beyond the limits: The Southern Network on Adverse Reactions (SONAR) projects. *Adv Pharmacoepidem Drug Safety* 2014; 3:149. doi: 10.4172/2167-1052.1000149.
26. **Lu ZK**, Yuan J, Li M, **Sutton SS**, Rao GA, Jacob S, **Bennett CL**. Cardiac risks associated with antibiotics: azithromycin and levofloxacin. *Expert Opin Drug Saf*. 2014 Dec 10:1-9. Epub.
27. Magwood JS, Lebbly A, Chen B, Kessler S, **Norris L**, **Bennett CL**. Emerging drugs for treatment of anemia chronic kidney disease. *Expert Opin Emerg Drugs*. 2013 Dec;18(4):421-9. doi: 10.1517/14728214.2013.836490. Epub 2013 Sep 16.
28. **Maxwell WD**, Jacob M, Spiryda LB, **Bennett CL**. Selection of contraceptive therapy for patients with thrombophilia: a review of the evidence. *J Womens Health*. 2014 Apr;23(4):318-26. doi: 10.1089/jwh.2013.4479. Epub 2014 Feb 19.
29. Mohammad RA, Bulloch MN, Chan J, Deming P, **Love BL**, Smith S, Dong BJ. Provision of Clinical Pharmacist Services For Individuals With Chronic Hepatitis C Viral (HCV) Infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy. *Pharmacotherapy* 2014;34:1341-54.
30. Prasad SM, Sartor O, **Bennett CL**. Reply to W. Read. *J Clin Oncol*. 2014 Feb 20;32(6):604-5. doi: 10.1200/JCO.2013.53.7225. Epub 2014 Jan 6. No abstract available
31. Prasad SM, Sartor O, **Bennett CL**. Editorial comment. *Urology*. 2014 Apr;83(4):786-7. doi: 10.1016/j.urology.2013.11.041. No abstract available.

32. Quidley AM, Bland CM, **Bookstaver PB**, Kuper K. Perioperative management of bariatric surgery patients. *Am J Health Syst Pharm* 2014;71:1253-64.
33. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, **Maxwell WD**, et al. The Clinical Pharmacogenomics Implementation Consortium Guideline for SLC01B1 and Simvastatin-Induced Myopathy: 2014 Update. *Clin Pharmacol Ther.* 2014 Oct;96(4):423-8.
34. Rao GA, Mann JR, Shoaibi A, **Bennett CL**, Nahhas G, **Sutton SS**, Jacob S, Strayer, S. Azithromycin and Levofloxacin use and increased risk of cardiac arrhythmia and death. *Ann Fam Med.* 2014 Mar-Apr;12(2):121-7. doi: 10.1370/afm.1601.
35. Salvo M, Edwards K, Gallegos P, Attridge R, Kesteloot LL, Bruce KW, Pinner N, Kiser K, Hylton A, **Bookstaver PB**. Assessment and revision of clinical pharmacy practice Internet web sites. *Ann Pharm* 2014;48:258-67.
36. **Sutton SS**, Stacy JJ, Mensch J, Torres-McGehee T, Bennett CL. Tackling community acquired methicillin resistant *Staphylococcus aureus* (CA-MRSA) in collegiate football players following implementation of an anti-MRSA program. *Br J Sports Med* 2014; 48(4):284-5.
37. **Sutton SS**. What are extended-spectrum beta-lactamases? *JAAPA* 2014 27(3):14-7.
38. Wei Y, Guo J, Zheng X, **Wu J**, Zhou Y, Yu Y, Ye Y, Zhang L, Zhao L. Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes. *International Journal of Nanomedicine* 2014; 9: 3623-30.
39. Wisniewski CS, Robert S, **Ball S**. Collaboration between a drug information center and an academic detailing program. *Am J Health-Syst Pharm* 2014;71:128-33.
40. **Wu J**, Noxon V, **Lu ZK**. Patterns of use and health expenses associated with triptans among adults with migraines. *The Clinical Journal of Pain* 2014 Sept 1 (Epub ahead of print)
41. **Wu J**, Davis-Ajami ML. Antidepressant therapy persistence in low-income, insured pregnant women. *J Manag Care Pharm* 2014;20: 631-7.
42. Zhang S, **Wu J**, Wang H, Wang T, Jin L, Shu D, Shan W, Xiong S. Liposomal oxymatrine in hepatic fibrosis treatment: formulation, in vitro and in vivo assessment. *AAPS PharmSciTech* 2014; 15 (3): 620-9.